J
Julio Benítez
Researcher at University of Extremadura
Publications - 108
Citations - 4483
Julio Benítez is an academic researcher from University of Extremadura. The author has contributed to research in topics: Debrisoquine & Genotype. The author has an hindex of 40, co-authored 108 publications receiving 4357 citations. Previous affiliations of Julio Benítez include University of Illinois at Urbana–Champaign & Hospital Clínico San Carlos.
Papers
More filters
Journal ArticleDOI
Genetic basis for differences in debrisoquin polymorphism between a spanish and other white populations
José A. G. Agúndez,José A. G. Agúndez,Carmen Martínez,Carmen Martínez,María C. Ledesma,María C. Ledesma,Margarita G. Ladona,Margarita G. Ladona,José M. Ladero,José M. Ladero,Julio Benítez,Julio Benítez +11 more
TL;DR: It is concluded that the same CTP2D6 mutations are present in Spaniards and other white subjects, Nevertheless, the frequencies of such mutations are different in the authors' population.
Journal ArticleDOI
Tryptamine: a possible endogenous substrate for CYP2D6.
TL;DR: The findings confirm the occurrence of a competitive inhibition of dextromethorphan O-demethylation in the presence of tryptamine and suggest that tryptamines may be an endogenous substrate of CYP2D6.
Journal ArticleDOI
Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
TL;DR: It is suggested that the measurement of thioridazine and its metabolite might be a useful tool to assess CYP2D6 activity during treatment, because potentially dangerous metabolic interactions may occur.
Journal ArticleDOI
CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians.
José A. G. Agúndez,Inmaculada Rodríguez,Manuela Olivera,José M. Ladero,María. A. Garcia,José Manuel Ribera,Julio Benítez +6 more
TL;DR: No genetically determined differences in the activation of drugs metabolized by these enzymes are to be expected in very old people, and longevity does not seem to be related to any special configuration of these three polymorphic traits.
Journal ArticleDOI
Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients.
José A. G. Agúndez,Lourdes Gallardo,María C. Ledesma,L. Lozano,Álvaro Rodríguez-Lescure,José C. Pontes,María C. Iglesias-Moreno,Joaquin Poch,José M. Ladero,Julio Benítez +9 more
TL;DR: It is concluded that dosages for CYP2D6 substrates should be adapted to lung and larynx cancer patients, as global findings indicate that over 20% patients with lung or larynX cancer show CYP 2D6 genotypes leading to ultrarapid metabolism or to the expression of an enzyme with altered kinetics.